Nanoviricides (NNVC) Net Cash Flow (2010 - 2026)
Nanoviricides (NNVC) posted Net Cash Flow of -$2.0 million for Q1 2026, down 148.62% sequentially from $4.1 million in Q4 2025, and down 39.94% YoY from -$3.3 million in Q1 2025.
Nanoviricides (NNVC) Net Cash Flow (2010 - 2026) Analysis & Trends
Nanoviricides has reported Net Cash Flow for 17 years, with the latest figure at -$2.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 39.94% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $670666.0 (up 193.85% YoY) and the FY2025 annual result came in at -$3.2 million, up 3.37% from the prior year.
- Net Cash Flow retreated to -$2.0 million in Q1 2026 per NNVC's latest filing, from $4.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $4.1 million in Q4 2025 and troughed at -$2.0 million in Q1 2024.
- A 5-year average of -$815223.8 and a median of -$1.4 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 4340.27% in 2025, down 163.88% in 2025.
- Over 5 years, Net Cash Flow stood at -$1.4 million in 2022, then retreated by 21.07% to -$1.7 million in 2023, then jumped by 105.32% to $91763.0 in 2024, then jumped by 4340.27% to $4.1 million in 2025, then plunged by 148.62% to -$2.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$2.0 million, $4.1 million, and -$438998.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 225.59 Mn |
| 10 | Nanoviricides | 29.50 Mn | 26.28 Mn | - | -1.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.98 Mn |
| Mar 31, 2026 | -1.98 Mn |
| Dec 31, 2025 | 4.07 Mn |
| Dec 31, 2025 | 4.07 Mn |
| Sep 30, 2025 | -438,998.00 |
| Sep 30, 2025 | -438,998.00 |
| Jun 30, 2025 | -984,026.00 |
| Jun 30, 2025 | -984,026.00 |
| Mar 31, 2025 | -1.42 Mn |
| Mar 31, 2025 | -1.42 Mn |
| Dec 31, 2024 | 91,763.00 |
| Dec 31, 2024 | 91,763.00 |
| Sep 30, 2024 | -931,489.00 |
| Sep 30, 2024 | -931,489.00 |
| Jun 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Dec 31, 2023 | -1.72 Mn |
| Dec 31, 2023 | -1.72 Mn |